Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test

CIRCULATE-III is an international, multicenter, open-label, randomized phase III trial designed to use ctDNA as a selection criterion for intensification or de-escalation of adjuvant chemotherapy. Eligible patients are randomly assigned to the following treatment groups: * Patients who test negative for ctDNA receive either capecitabine for 6 months (experimental group) or oxaliplatin + capecitabine for 3 months (standard group). * Patients who test positive for ctDNA receive either FOLFIRINOX for 6 months (experimental group) or FOLFOX for 6 months (standard group). Patient participation in the trial will not exceed 66 months after randomization, including a maximum treatment duration of 6 months and a follow-up period of 60 months.

NCT Number	NCT07340567
Lead Sponsor	UNICANCER Collaborators: Natera, Inc.
Conditions	Colorectal Cancer
Enrollment	2,450 participants
Start Date	2026-07-20
Primary Completion	2032-11-01 (estimated)
Study Completion	2035-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-22